Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility |
| |
Authors: | Email author" target="_blank">Li-Xin?QiuEmail author Ke?Wang Sheng?Yang Chen?Mao Lei?Zhao Lei?Yao Jian?Zhang Qun-Ling?Zhang Si?Sun Kai?Xue |
| |
Institution: | (1) Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;(2) Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;(3) Institute of Respiratory Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China;(4) Department of Medical Oncology, Union Hospital, Fu Jian Medical University, Fuzhou, China;(5) Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China;(6) Department of Epidemiology, School of Public Health, Wuhan University, Wuhan, China;(7) State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, China |
| |
Abstract: | Several polymorphisms of vascular endothelial growth factor (VEGF) such as 936 C/T, −2578 C/A, −406 C/T, and −1154 G/A polymorphism
have been identified. Published data on the association between VEGF polymorphisms and breast cancer risk are inconclusive.
To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude OR with 95% CI was used to assess
the strength of association between them. For VEGF 936C/T polymorphism, a total of 10 studies including 7,685 cases and 7,915
controls were involved in this meta-analysis. Overall, no significant associations were found between VEGF 936C/T polymorphism
and breast cancer risk when all studies pooled into the meta-analysis (TC vs. CC: OR = 0.904, 95% CI = 0.797–1.024; TT vs.
CC: OR = 0.974, 95% CI = 0.786–1.205; dominant model: OR = 0.911, 95% CI = 0.811–1.024; and recessive model: OR = 0.991, 95%
CI = 0.801–1.226). In the subgroup analysis by ethnicity, still no significant associations were found for all comparison
models. For −2578 C/A, −406 C/T, and −1154 G/A polymorphism, there were too limited data to perform a meta-analysis. In conclusion,
this meta-analysis suggests that the VEGF 936C/T polymorphism may be not associated with breast cancer development. However,
large sample and representative population-based studies with homogeneous breast cancer patients and well matched controls
are warranted to confirm this finding. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|